Mirogabalin hits goals in late-stage pain syndromes trials

30 June 2017

Shares of Japanese pharma major Daiichi Sankyo (TYO: 4568) were up 1.2% at 2,647 yen early afternoon today, after the company announced top-line results from NEUCOURSE, a Phase III clinical trial in patients with post-herpetic neuralgia, and the ALDAY Phase III clinical trials in patients with fibromyalgia.

The NEUCOURSE and ALDAY clinical trials are integral aspects of Daiichi Sankyo’s broader global clinical development program for mirogabalin, evaluating its use in pain syndromes including post-herpetic neuralgia, fibromyalgia and diabetic peripheral neuropathic pain.

Mirogabalin has been touted as a possible superior and safer competitor to Pfizer's (NYSE: PFE) blockbuster Lyrica (pregabalin), which generated sales of $4.17 billion last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK